All-oral combination of lapatinib and capecitabine in patients with brain metastases from HER2-positive breast cancer – A phase II study
Conclusion The combination of LC is active and well-tolerated treatment in patients with HER2+ve BCBM.
Source: Journal of the Egyptian National Cancer Institute - Category: Cancer & Oncology Source Type: research
More News: Brain | Brain Cancers | Breast Cancer | Cancer | Cancer & Oncology | HER2 | Herceptin | Neurology | Oral Cancer | Skin | Study | Toxicology | Xeloda